Review Article
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
Table 1
Current immunologic therapeutic approaches in PCa.
| Therapy | Molecule | Mechanism of action | Clinical trials [Ref.] |
| Sipuleucel-T (Provenge) | Autologous cellular immune-therapy | Stimulates a T cell immune response against cancer cells (+ for PAP) | Phases I-II: [61] Phase II: [63ā65] |
| Ipilimumab (Yervoy) | IgG1 Human monoclonal antibody | Blocks the activity of CTLA-4 and Treg expression | Phases I-II: [67] Phase III: [68] |
| Tasquinimod | Oral quinolone-3-carboxamide | Antitumor action through inhibition of angiogenesis and immunomodulation | Phase III: [69, 70] |
| Prostvac-VF | Vector based vaccing | A combination of two viral particles, vaccinia, and fowlpox that infect the APC cells promoting an immune response against PSA expressing cells | Phase II: [71] |
| GVAX | Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transfected tumor cell vaccine | Evocation of a strong immunoreaction by antigens expressed on human prostate cell lines modified by GM-CSF | Phase III: [72, 73] |
|
|